CELL INTELLIGENCE · 肿瘤细胞治疗研究

免疫细胞衰老驱动黑色素瘤对免疫治疗的应答

Immune cell senescence drives responsiveness to immunotherapy in melanoma.

弥漫大 B 细胞淋巴瘤的免疫治疗：从单克隆抗体到细胞治疗（叙述性综述）

Immunotherapy of diffuse large B-cell lymphoma: from monoclonal antibodies to cellular therapies. A narrative review.

非基因修饰类 CAR NK 细胞的制备

Generation of non-genetically modified, CAR-like, NK cells.

Pin 技术提供了一个现货型 NK 细胞治疗平台，可在无需基因修饰的情况下生成类 CAR NK 细胞，易于靶向多种肿瘤抗原。

针对 B 细胞恶性肿瘤治疗的具有靶细胞限制性 IL-15 活性的免疫细胞因子

Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.

用于血液系统恶性肿瘤免疫治疗的双特异性和三特异性免疫细胞衔接器

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.

Serpin B9 调控 CAR-T 细胞对肿瘤细胞的杀伤

Serpin B9 controls tumor cell killing by CAR T cells.

这些数据表明，serpin B9 是 CAR-T 细胞介导的肿瘤细胞杀伤的耐药介质，应通过抑制或绕过它来改善 CAR-T 细胞应答。

肾脏病学趋势：从虚无主义到抗体介导排斥反应的靶向治疗

Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection.

解析 MYC 介导的对传统抗体与 T 细胞重定向治疗性抗体的逃逸机制

Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies.

单次高强度运动增强利妥昔单抗在体外对人慢性淋巴细胞白血病 B 细胞的疗效

A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo.

新型 NKG2D 靶向双特异性抗体增强 NK 细胞和 T 细胞对恶性 B 细胞的抗体介导杀伤

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.